The US FDA has approved
Vonvendi, von Willebrand factor
(recombinant) for use in the
treatment and control of bleeding
episodes in adults 18 years of age
and older who have von Willebrand
disease.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 09 Dec 15
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Dec 15
